Surrozen, Inc.

SRZN Healthcare Biotechnology

Surrozen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 67.4% from fiscal 2024. In the quarter to June 2026, revenue grew 408.7%, EPS grew 7.84% and free cash flow fell 21.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

23.44 1.63 −6.50%
Market cap
$294.7M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
n/a
Altman Z
−7.50
Beneish M
−14.31
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
26.29 42.56 48.61 30.65
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(40.82) (25.53) (29.08) (12.22)
P/B ratio
0.00 0.00 0.00 0.00
Price to Tangible BV
0.00 0.00 0.00 0.00
EV/Sales
17.43 28.29 22.94 8.09
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(5.77) (6.34) (2.64) (1.39)
EV/FCF
(5.73) (6.30) (2.63) (1.39)
Quick Ratio
11.88 11.70 9.01 12.85
Current Ratio
12.14 11.91 9.22 13.15
Net Debt/EBITDA
9.89 10.29 7.09 7.51
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.11 0.06 0.05 0.05
Operating CF/Net income
(0.23) 0.10 0.04 0.13
Capex/Depreciation
(0.37) (1.85) (1.31) (0.39)
Research and Development Expense of Revenue
169.68% 186.56% 1,702.84% 790.84%
Selling, General and Administrative Expense of Revenue
137.72% 122.56% 790.91% 416.48%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
57.86% 42.10% 189.77% 102.24%
Graham Net Nets
(0.74) (0.89) (1.15) (0.29)
Graham Number
125.59 146.58 137.30 37.14
Earnings Yield
(144.08%) (129.04%) (147.65%) (173.31%)
Free Cash Flow Yield
(11.56%) (10.56%) (17.97%) (19.04%)
Revenue per Share
0.43 0.46 0.07 0.11
Operating CF per Share
(0.64) (1.14) (0.78) (1.05)
Capex per Share
0.00 (0.01) (0.01) 0.00
Free Cash Flow per Share
(0.64) (1.15) (0.79) (1.06)
Cash per Share
8.75 9.76 11.93 9.49
Shareholders Equity per Share
(18.75) (25.40) (25.11) (2.74)
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
(18.75) (25.40) (25.11) (2.74)
Free Cash Flow
(7.43) (12.61) (5.87) (9.06)
Working Capital
100.39 104.38 81.63 79.33
Capital Expenditures
(0.02) (0.12) (0.06) (0.02)
Net Current Asset Value
(224.87) (284.91) (194.93) (31.70)
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.02 0.11 0.02
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
3.78 3.82 1.37 7.38
Average Payables
0.71 0.60 0.52 0.41
Average Assets
109.15 117.77 73.60 71.02
Average Common Equity
(85.78) (136.24) (104.57) (8.92)

Fold the line items

Columns are period end dates